Hua Medicine (Shanghai) Ltd. (HUMDF) Q2 2026 Earnings Call Transcript

SA Transcripts 161.96K Followers Follow Hua Medicine (Shanghai) Ltd. ( HUMDF ) Q2 2026 Earnings Call August 20, 2026 11:30 PM EDT Company Participants Chen Li - Founder, CEO, Member of Portfolio Advisory Board & Executive Director Cheng Lin Chien - Executive VP, Chief Strategy Officer & Executive Director Conference Call Participants Matthew Yan Presentation Matthew Yan Hello, everyone. Thank you for joining the Hua Medicine First Half 2026 Results Investor Call. This will be the English session. This is Matthew Yan, the China Health care Analyst at CITIC International. And we are very honored to have invited the management team of Hua Medicine to join. This includes the CEO and Founder, Dr. Chen Li; and also the Chief Strategy Officer, Dr. George Lin. And without further ado, we will start the call. [Operator Instructions] So now I will hand the call to Dr. Chen. Thank you. Please go ahead. Chen Li Founder, CEO, Member of Portfolio Advisory Board & Executive Director Thank you, Matthew, and thank you, everyone, for coming to Hua Medicine 2026 interim half year report. And Hua Medicine has a great half year with accelerated sales growth and our commercialization representing 73% in sales volume in packs and then also showing that the expansion of our commercialization team, increasing the collaboration between medical marketing and then commercial with the medical sales representative, enhance the productivity and then reduce the cost in the overall process. In this first half year, we can see that it's 36% compared with last half year and then 27% growth compared last second half with 2025 first half. And then we just remind you that we actually doubled the 2025 sales over 2024. So after Hua Medicine established our own capabilities in the commercialization, Hua Medicine business is getting very quick expansion. Now with success in the Mainland China and then